(Q30428353)

21 June 2017

A polyvalent influenza A DNA vaccine induces heterologous immunity and protects pigs against pandemic A(H1N1)pdm09 virus infection (English)

1 reference

21 June 2017

0 references

Lasse Vinner

2

0 references

Anders Fomsgaard

object named as

Anders Fomsgaard

5

0 references

author name string

Karoline Bragstad

1

1 reference

21 June 2017

Mette Sif Hansen

3

1 reference

21 June 2017

Jens Nielsen

4

1 reference

21 June 2017

language of work or name

English

0 references

publication date

13 March 2013

1 reference

21 June 2017

8

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

21 June 2017

31

1 reference

21 June 2017

18

1 reference

21 June 2017

2281-2288

1 reference

Two years after pandemic influenza A/2009/H1N1: what have we learned?

21 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Infection with seasonal influenza virus elicits CD4 T cells specific for genetically conserved epitopes that can be rapidly mobilized for protective immunity to pandemic H1N1 influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Seasonal H1N1 influenza virus infection induces cross-protective pandemic H1N1 virus immunity through a CD8-independent, B cell-dependent mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Immunity to pre-1950 H1N1 influenza viruses confers cross-protection against the pandemic swine-origin 2009 A (H1N1) influenza virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Cross-reactive T cells are involved in rapid clearance of 2009 pandemic H1N1 influenza virus in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Molecular and cellular mechanisms of DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Cellular immune response in the presence of protective antibody levels correlates with protection against 1918 influenza in ferrets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

DNA vaccines: recent developments and future possibilities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Immunogenicity and clinical protection against equine influenza by DNA vaccination of ponies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Technologies for enhanced efficacy of DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

DNA vaccination elicits protective immune responses against pandemic and classic swine influenza viruses in pigs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Novel strategies to improve DNA vaccine immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Electroporation delivery of DNA vaccines: prospects for success

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Intradermal DNA vaccination enhanced by low-current electroporation improves antigen expression and induces robust cellular and humoral immune responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

DNA vaccines: ready for prime time?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Current progress of DNA vaccine studies in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Epidermal DNA vaccine for influenza is immunogenic in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Pandemic influenza 1918 H1N1 and 1968 H3N2 DNA vaccines induce cross-reactive immunity in ferrets against infection with viruses drifted for decades

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Immune responses to influenza virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Induction of broadly neutralizing H1N1 influenza antibodies by vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Heterologous protection against influenza by injection of DNA encoding a viral protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Different evolutionary trajectories of European avian-like and classical swine H1N1 influenza A viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Structure of influenza virus haemagglutinin complexed with a neutralizing antibody.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Antibody recognition of a highly conserved influenza virus epitope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Inhibition of fusion activity of influenza A haemagglutinin mediated by HA2-specific monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Genetic and pathobiologic characterization of pandemic H1N1 2009 influenza viruses from a naturally infected swine herd.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Pathogenesis and subsequent cross-protection of influenza virus infection in pigs sustained by an H1N2 strain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Seasonal and pandemic human influenza viruses attach better to human upper respiratory tract epithelium than avian influenza viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Reproduction of postweaning multisystemic wasting syndrome (PMWS) in immunostimulated and non-immunostimulated 3-week-old piglets experimentally infected with porcine circovirus type 2 (PCV2).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Optimization of skin electroporation in mice to increase tolerability of DNA vaccine delivery to patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Association of lymphopenia with porcine circovirus type 2 induced postweaning multisystemic wasting syndrome (PMWS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

Depletion of CD4(+) and CD8(high+) T-cells before the onset of viraemia during classical swine fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.061

10.1016/J.VACCINE.2013.02.061

7 January 2021

Identifiers

DOI

1 reference

21 June 2017

1 reference